Drug delivery technologies can be classified on the basis of the four delivery routes: oral, transdermal, inhalation, and parenteral. These innovative technologies are highly useful in protein and gene-based therapies. Upcoming drug delivery technologies are focusing on boosting sales volume through improved safety and efficacy. The market has a large number of suppliers offering products with multiple applications; but it still offers plentiful opportunities to new entrants wishing to tap niche market segments.
Drug delivery devices refer to medical devices or systems designed to administer medications or therapeutic substances to patients. These devices are specifically developed to facilitate the delivery of drugs in various forms, such as injections, inhalation, transdermal patches, implants, and oral routes. They play a crucial role in ensuring accurate and targeted drug delivery, improving the effectiveness and convenience of medication administration.
Drug delivery devices can be simple or complex, ranging from basic devices like syringes and inhalers to more advanced systems like infusion pumps and implantable devices. These devices are designed to safely and efficiently deliver medications to the specific site of action in the body, ensuring the desired therapeutic effects while minimizing side effects and maximizing patient compliance.
The choice of drug delivery device depends on factors such as the type of medication, the desired route of administration, the characteristics of the patient population, and the specific therapeutic requirements. Some common examples of drug delivery devices include:
- Syringes and needles: Used for administering drugs through intramuscular, subcutaneous, or intravenous injections.
- Inhalers and nebulizers: Devices used for delivering medications directly to the lungs, commonly used in the treatment of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD).
- Transdermal patches: These patches are applied to the skin and release drugs gradually into the bloodstream, providing a controlled and continuous drug delivery over a specific period.
- Infusion pumps: These devices are used for the continuous administration of medications or fluids intravenously, typically in hospitals or home care settings.
- Implantable devices: Such as drug-eluting stents or implants, which release drugs locally at the site of implantation to prevent restenosis or provide targeted therapy.
- Oral drug delivery systems: Including tablets, capsules, and controlled-release formulations that release the drug in a controlled manner as it passes through the gastrointestinal tract.
The development of drug delivery devices aims to improve treatment outcomes, enhance patient convenience, and optimize the therapeutic benefits of medications. These devices undergo rigorous testing and regulation to ensure their safety, efficacy, and compliance with relevant standards and guidelines.
Futuristic scope -
The field of drug delivery devices continues to evolve with advancements in technology, materials, and healthcare needs. The futuristic scope of drug delivery devices encompasses several exciting possibilities:
- Smart Drug Delivery Devices: Future drug delivery devices are likely to incorporate smart features, such as connectivity, sensors, and data analysis capabilities. These devices can monitor patient-specific parameters, adjust drug dosages based on real-time data, and provide feedback to healthcare providers for personalized treatment.
- Nanotechnology-Based Drug Delivery: Nanotechnology holds promise for the development of advanced drug delivery systems. Nanoparticles, nanocarriers, and nanosensors can be used to precisely target specific cells or tissues, enhance drug stability and bioavailability, and enable controlled release of drugs over extended periods.
- Implantable and Wearable Devices: Miniaturized implantable and wearable drug delivery devices are expected to become more prevalent. These devices can provide long-term, sustained drug release, eliminating the need for frequent administration. They can be used for various applications, such as insulin delivery for diabetes management or hormone therapy.
- Targeted Drug Delivery: Future drug delivery devices may focus on targeted drug delivery to specific sites in the body. By incorporating molecular targeting mechanisms, these devices can selectively deliver drugs to affected tissues or cells, minimizing systemic side effects and maximizing therapeutic efficacy.
- Biodegradable and Bioresorbable Systems: Bioresorbable drug delivery devices are designed to degrade and be absorbed by the body over time, eliminating the need for device removal. These devices can be used for localized drug delivery or as temporary implants for tissue regeneration, wound healing, or post-surgical applications.
- 3D Printing Technology: 3D printing has the potential to revolutionize drug delivery device manufacturing. It enables the production of customized, patient-specific devices with complex geometries and drug-release profiles. This technology allows for rapid prototyping, personalized drug delivery systems, and on-demand manufacturing of drug delivery devices.
- Controlled and Programmable Drug Release: Future drug delivery devices may offer precise control over drug release rates and patterns. Through advanced materials, microfluidics, and microelectromechanical systems (MEMS), devices can be engineered to deliver drugs at predetermined intervals, specific dosages, or in response to physiological cues.
- Integration with Digital Health Platforms: Drug delivery devices of the future are likely to integrate with digital health platforms and electronic medical records. This integration can enable real-time monitoring, remote patient management, and seamless data sharing between patients, healthcare providers, and drug delivery device manufacturers.
These futuristic developments have the potential to enhance drug efficacy, improve patient adherence, and revolutionize healthcare delivery. However, it's important to note that the practical implementation of these advancements requires extensive research, regulatory approvals, and addressing challenges such as biocompatibility, cost-effectiveness, and scalability.
Merger & Acquisition –
The field of drug delivery devices has seen significant merger and acquisition (M&A) activities in recent years. Companies often engage in M&A to enhance their product portfolios, expand market reach, acquire new technologies, and strengthen their competitive position. Here are a few examples of notable M&A deals in the drug delivery devices sector:
- Medtronic's Acquisition of Covidien: In 2015, Medtronic, a global medical technology company, acquired Covidien, a leading manufacturer of medical devices and supplies. This merger allowed Medtronic to expand its offerings in the drug delivery and patient monitoring segments, strengthening its position in the healthcare industry.
- Becton, Dickinson and Company (BD) - C.R. Bard Merger: In 2017, BD, a global medical technology company, completed the acquisition of C.R. Bard, a manufacturer of medical devices and technologies. This merger expanded BD's presence in the drug delivery and surgical specialties markets, complementing its existing portfolio of medical products.
- Johnson & Johnson's Acquisition of Actelion: In 2017, Johnson & Johnson acquired Actelion, a biopharmaceutical company specializing in pulmonary arterial hypertension treatments. This acquisition expanded Johnson & Johnson's presence in the field of pulmonary drug delivery devices, leveraging Actelion's expertise in this therapeutic area.
- Roche's Acquisition of Genentech: In 2009, Roche, a global pharmaceutical company, acquired Genentech, a biotechnology company known for its innovative drug development and delivery technologies. This acquisition enabled Roche to enhance its capabilities in targeted drug delivery and personalized medicine.
- Terumo's Acquisition of MicroVention: In 2006, Terumo Corporation, a Japanese medical device company, acquired MicroVention, a manufacturer of neurovascular devices and technologies. This acquisition expanded Terumo's product portfolio in the field of neurovascular drug delivery devices and positioned the company as a leader in this specialized market.
These are just a few examples of notable M&A deals in the drug delivery devices sector. M&A activities are common in this industry as companies seek to consolidate their positions, gain access to new technologies, and diversify their offerings. These strategic partnerships and acquisitions contribute to the development of innovative drug delivery devices and the advancement of healthcare solutions.
Key segments in Drug Delivery Devices:
The drug delivery devices market can be segmented into several key segments based on various factors such as the route of administration, type of device, and therapeutic applications. Here are some of the key segments in the drug delivery devices market:
- Injectable Drug Delivery Devices: This segment includes devices used for the delivery of drugs through injections, including syringes, needles, pen injectors, autoinjectors, and needle-free injection systems. These devices are commonly used for subcutaneous, intramuscular, or intravenous administration of medications.
- Inhalation Drug Delivery Devices: Inhalation devices are used for the delivery of drugs directly to the respiratory system. This segment includes metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and nasal sprays. Inhalation devices are widely used for the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
- Transdermal Drug Delivery Devices: Transdermal drug delivery devices are designed to deliver medications through the skin and into the bloodstream. Transdermal patches and devices utilize adhesive systems to release drugs slowly and consistently over a specified period. They offer advantages such as convenient administration, reduced side effects, and improved patient compliance.
- Oral Drug Delivery Devices: Oral drug delivery devices include tablets, capsules, and other oral dosage forms designed to deliver drugs through the gastrointestinal tract. These devices can be modified to provide controlled release or targeted drug delivery to specific sites in the gastrointestinal system.
- Implantable Drug Delivery Devices: Implantable drug delivery devices are designed to be surgically implanted in the body for long-term drug administration. These devices can release drugs locally or systemically over an extended period, providing sustained therapeutic effects. Examples include drug-eluting stents, intrauterine devices (IUDs), and implantable pumps.
- Infusion and Parenteral Drug Delivery Devices: Infusion and parenteral drug delivery devices are used for the continuous or intermittent administration of medications intravenously or through other parenteral routes. This segment includes infusion pumps, intravenous sets, and other devices used for controlled and precise drug delivery.
- Other Specialized Drug Delivery Devices: This segment encompasses various specialized drug delivery devices tailored for specific therapeutic applications. Examples include ocular drug delivery devices, insulin delivery devices for diabetes management, drug-eluting devices for localized therapy, and targeted delivery systems for specific tissues or organs.
These segments highlight the diverse range of drug delivery devices available in the market, each designed to cater to specific routes of administration and therapeutic requirements. Advancements in technology and increased focus on personalized medicine are driving innovation in these segments, leading to the development of more precise and effective drug delivery devices.
subsegments in Drug Delivery Devices:
Within the key segments of drug delivery devices, there are several subsegments that further categorize the devices based on specific features, technologies, or applications. Here are some subsegments in the drug delivery devices market:
- Injectable Drug Delivery Devices:
- Prefilled Syringes: Syringes that come pre-filled with a specific dosage of medication, offering convenience and accurate dosing.
- Needle-Free Injection Systems: Devices that deliver medications without the use of traditional needles, utilizing methods such as jet injection or microneedles.
- Autoinjectors: Devices designed for self-administration of pre-measured doses of medication, typically used for conditions like rheumatoid arthritis or allergies.
- Inhalation Drug Delivery Devices:
- Metered-Dose Inhalers (MDIs): Pressurized devices that deliver a precise dose of medication in aerosol form, commonly used for asthma and COPD treatments.
- Dry Powder Inhalers (DPIs): Devices that deliver medication in powdered form, activated by the patient's inhalation.
- Nebulizers: Devices that convert liquid medication into a fine mist for inhalation, often used for individuals who have difficulty using inhalers.
- Transdermal Drug Delivery Devices:
- Transdermal Patches: Devices containing medication that adheres to the skin and delivers drugs slowly over a specified period.
- Iontophoresis Devices: Devices that use a mild electrical current to enhance drug penetration through the skin.
- Microneedle Patches: Patches containing tiny microneedles that painlessly penetrate the skin to deliver drugs.
- Oral Drug Delivery Devices:
- Modified-Release Formulations: Tablets or capsules designed to release the drug in a controlled manner, providing sustained release or targeted delivery.
- Orally Disintegrating Tablets (ODTs): Tablets that rapidly dissolve in the mouth, allowing for easy administration, especially for individuals with swallowing difficulties.
- Gastrointestinal Drug Delivery Systems: Devices or formulations designed to deliver drugs to specific regions of the gastrointestinal tract for targeted therapy.
- Implantable Drug Delivery Devices:
- Drug-Eluting Stents: Stents used in cardiovascular procedures that release medication to prevent restenosis and promote healing.
- Implantable Pumps: Devices surgically implanted to deliver medications directly into the body, often used for pain management or chemotherapy.
- Infusion and Parenteral Drug Delivery Devices:
- Infusion Pumps: Devices that deliver medications or fluids in a controlled manner, typically used in hospitals or home care settings.
- Central Venous Catheters: Catheters inserted into a major vein for long-term administration of medications or parenteral nutrition.
- Insulin Delivery Systems: Devices such as insulin pens or insulin pumps used for subcutaneous administration of insulin in diabetes management.
These subsegments reflect the diverse range of drug delivery devices available within each key segment. Each subsegment may have unique features, mechanisms, or applications that cater to specific patient needs, dosage requirements, or treatment modalities.
Drug Delivery Devices form an essential part of the broader healthcare ecosystem, collaborating with various stakeholders to ensure effective and safe medication delivery. Here's a brief overview of the ecosystem surrounding drug delivery devices:
- Pharmaceutical Companies: Pharmaceutical companies play a vital role in developing and manufacturing drugs that are compatible with drug delivery devices. They collaborate with device manufacturers to optimize drug formulations, considering factors such as solubility, stability, and compatibility with specific delivery systems.
- Medical Device Manufacturers: These companies specialize in the design, development, and production of drug delivery devices. They work closely with pharmaceutical companies to create devices that are user-friendly, precise, and capable of delivering medications in the desired manner.
- Regulatory Authorities: Regulatory bodies, such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe, oversee the safety, efficacy, and quality of drug delivery devices. They establish guidelines, conduct assessments, and grant approvals to ensure compliance with regulatory standards.
- Healthcare Professionals: Healthcare professionals, including physicians, nurses, and pharmacists, are involved in prescribing, administering, and monitoring the use of drug delivery devices. They provide instructions, educate patients, and ensure proper utilization of these devices for optimal therapeutic outcomes.
- Patients: Patients are the end-users of drug delivery devices. They rely on these devices to self-administer medications or receive treatments in healthcare settings. Patient feedback and adherence to device usage instructions are critical for successful drug delivery and treatment effectiveness.
- Research Institutions and Academia: Research institutions and academic organizations contribute to the development and innovation of drug delivery devices. They conduct studies, clinical trials, and research on new technologies, materials, and drug-device interactions to improve the safety and efficacy of drug delivery.
- Healthcare Facilities: Hospitals, clinics, and other healthcare facilities provide the infrastructure and resources for drug delivery device administration. They ensure proper storage, maintenance, and disposal of devices, as well as train healthcare professionals in their usage.
- Payors and Health Insurance Companies: Payors, such as health insurance companies or government healthcare systems, evaluate the cost-effectiveness and reimbursement of drug delivery devices. They assess the value and clinical benefits of these devices and make decisions regarding coverage and reimbursement policies.
The drug delivery device ecosystem involves collaboration and coordination among these stakeholders to ensure the development, availability, and appropriate utilization of safe and effective drug delivery devices. This collaboration promotes innovation, patient safety, and improved healthcare outcomes in medication administration and treatment delivery.
The drug delivery devices market is highly competitive, with several top players operating globally. While the market landscape is dynamic and subject to change, here are some of the notable companies that have a significant presence in the drug delivery devices industry:
- Medtronic plc: Medtronic is a leading medical technology company that offers a wide range of drug delivery devices, including infusion pumps, insulin pumps, implantable drug delivery systems, and other devices for various therapeutic areas.
- Johnson & Johnson: Johnson & Johnson's subsidiary, Janssen Pharmaceuticals, develops and manufactures drug delivery devices for multiple therapeutic areas, including injectable devices, inhalation systems, and transdermal patches.
- BD (Becton, Dickinson and Company): BD is a global medical technology company that provides a broad portfolio of drug delivery devices, including syringes, needles, pen injectors, and infusion systems.
- Novartis AG: Novartis is a pharmaceutical company that has a strong presence in drug delivery devices, particularly in the inhalation segment. Their subsidiary, Sandoz, offers inhalation devices for the delivery of respiratory medications.
- 3M Company: 3M develops and manufactures a range of drug delivery devices, including transdermal patches, inhalers, and nasal drug delivery systems. Their products cater to various therapeutic areas, including pain management and respiratory disorders.
- Roche Holding AG: Roche is a multinational pharmaceutical company that produces drug delivery devices for various applications, such as insulin delivery systems for diabetes management and drug-eluting devices for cardiovascular interventions.
- Insulet Corporation: Insulet specializes in the development of innovative drug delivery devices for diabetes management. Their flagship product is the Omnipod System, a tubeless insulin pump that offers discreet and personalized insulin delivery.
- Eli Lilly and Company: Eli Lilly is a pharmaceutical company that manufactures drug delivery devices, including injection pens and devices for the delivery of insulin and other medications.
- Gerresheimer AG: Gerresheimer is a global provider of drug delivery devices, offering a range of products such as inhalers, syringes, and vials for pharmaceutical and biotechnology companies.
- West Pharmaceutical Services, Inc.: West Pharmaceutical Services focuses on the development and manufacturing of drug delivery systems, including prefilled syringe systems, injectable device components, and drug containment and delivery systems.
These are just a few examples of top players in the drug delivery devices industry. The market is diverse and encompasses many other established companies and emerging players that contribute to advancements in drug delivery technologies.
High grown opportunities:
The drug delivery devices market presents several high-growth opportunities driven by technological advancements, increasing demand for targeted therapies, and the need for improved patient outcomes. Some of the key areas offering significant growth potential in drug delivery devices include:
- Biologics and Large Molecule Delivery: The rise in biologic drugs and large molecules, such as monoclonal antibodies and gene therapies, necessitates innovative delivery systems. Developments in needle-free injection systems, wearable devices, and microneedle patches are enabling more convenient and efficient administration of these complex therapies.
- Personalized Medicine: The shift towards personalized medicine and precision therapies creates opportunities for tailored drug delivery solutions. Devices that offer individualized dosing, remote monitoring, and real-time data collection facilitate personalized treatment regimens and improved patient adherence.
- Implantable Devices: Implantable drug delivery devices, such as drug-eluting stents and implantable pumps, are experiencing growth due to their ability to provide sustained and localized drug release. These devices are being further developed to enhance biocompatibility, programmability, and compatibility with various drugs, expanding their applications in areas like pain management, oncology, and chronic disease management.
- Connected and Smart Drug Delivery Devices: The integration of connectivity, sensors, and data analytics in drug delivery devices is revolutionizing patient care. Smart inhalers, insulin pens with digital interfaces, and wearable infusion pumps with remote monitoring capabilities enable healthcare providers to track patient adherence, collect real-time data, and improve treatment outcomes.
- Nanotechnology-Based Delivery Systems: Nanotechnology offers unique opportunities in drug delivery, enabling targeted and controlled release of drugs at the molecular level. Nano-based carriers, such as liposomes, nanoparticles, and micelles, improve drug stability, enhance bioavailability, and enable precise targeting of specific tissues or cells.
- Home Healthcare and Self-Administration: The trend towards home healthcare and self-administration of medications is driving the demand for user-friendly and patient-centric drug delivery devices. Devices that are easy to use, portable, and offer simplified administration, such as autoinjectors, insulin pumps, and wearable devices, are gaining prominence.
- Emerging Markets: Growing healthcare infrastructure, increasing patient access to medical treatments, and rising awareness about advanced drug delivery technologies in emerging markets present substantial growth opportunities. Companies are expanding their presence in regions like Asia-Pacific, Latin America, and the Middle East to tap into these emerging markets.
- Advanced Drug Delivery Technologies: Ongoing research and development efforts are focused on developing novel drug delivery technologies, including microfluidics, 3D printing, implantable biosensors, and targeted drug delivery systems. These technologies have the potential to enhance drug efficacy, minimize side effects, and improve patient outcomes.
These high-growth opportunities in drug delivery devices are driven by evolving healthcare needs, technological advancements, and the desire to optimize drug therapies. Companies that can innovate and provide effective, patient-friendly, and targeted delivery solutions are poised to succeed in this rapidly evolving market.
Challenges in Drug Delivery Devices Industry:
The drug delivery devices industry faces several challenges that impact product development, regulatory compliance, market adoption, and patient outcomes. Some of the key challenges in the drug delivery devices industry include:
- Regulatory Compliance: Drug delivery devices are subject to stringent regulations and standards to ensure patient safety and efficacy. Obtaining regulatory approvals and navigating complex compliance requirements can be time-consuming and costly, posing challenges for companies seeking to bring innovative devices to market.
- Technical Complexities: Developing drug delivery devices that effectively deliver medications while considering factors like drug stability, bioavailability, and dosage accuracy can be technically challenging. Designing devices that are user-friendly, reliable, and compatible with various drug formulations requires expertise in engineering, materials science, and pharmaceutical sciences.
- Patient Adherence and User Experience: Patient adherence to prescribed medication regimens is crucial for successful treatment outcomes. Drug delivery devices need to be designed with patient needs and preferences in mind to enhance ease of use, minimize discomfort, and improve overall user experience. Ensuring that devices are intuitive, portable, and have clear instructions can help promote patient adherence.
- Cost and Reimbursement: Drug delivery devices often involve additional costs beyond the medication itself. Pricing and reimbursement considerations can impact market adoption and accessibility of innovative devices. Companies need to navigate reimbursement policies and demonstrate the value and cost-effectiveness of their devices to gain market acceptance.
- Compatibility and Interoperability: Drug delivery devices need to be compatible with various drugs, formulations, and delivery routes. Ensuring interoperability with different drug formulations and the ability to integrate with electronic health records and connected healthcare systems can be challenging, particularly in complex treatment regimens.
- Safety and Risk Mitigation: Ensuring the safety of drug delivery devices is of paramount importance. Minimizing risks associated with device malfunctions, contamination, or adverse reactions is critical. Comprehensive risk assessment, quality control measures, and post-market surveillance are essential to identify and mitigate potential safety concerns.
- Intellectual Property Protection: Developing innovative drug delivery devices requires significant investments in research and development. Protecting intellectual property rights and preventing unauthorized use or infringement is crucial for companies to maintain a competitive advantage and recoup their investments.
- Manufacturing and Supply Chain Considerations: Establishing robust manufacturing processes, maintaining quality control, and managing the supply chain can be challenging in the drug delivery devices industry. Ensuring consistent product quality, scalability, and reliable supply is essential to meet market demand and regulatory requirements.
- Clinical Evidence and Adoption: Generating robust clinical evidence to support the safety, efficacy, and superiority of drug delivery devices over existing treatment options can be demanding. Convincing healthcare providers and payors about the clinical benefits and economic value of innovative devices is crucial for widespread adoption and market penetration.
- Emerging Technologies and Competition: The drug delivery devices industry is dynamic, with rapid advancements in technology and evolving market dynamics. Staying at the forefront of innovation, navigating competitive landscapes, and anticipating market trends are ongoing challenges for companies in this industry.
Addressing these challenges requires collaboration among stakeholders, including device manufacturers, pharmaceutical companies, regulatory bodies, healthcare providers, and patient advocacy groups. Overcoming these challenges can drive innovation, improve patient outcomes, and enhance the overall effectiveness of drug delivery devices.
High CAGR geography
The drug delivery devices market exhibits high compound annual growth rate (CAGR) across various geographies. While market dynamics may vary, some regions are expected to experience significant growth in the drug delivery devices sector. Here are a few geographies with high projected CAGR for drug delivery devices:
- Asia-Pacific: The Asia-Pacific region is anticipated to witness substantial growth in the drug delivery devices market. Factors such as increasing healthcare expenditure, rising prevalence of chronic diseases, growing geriatric population, and improving healthcare infrastructure contribute to the market's expansion. Countries like China, India, Japan, South Korea, and Australia are key contributors to the region's growth.
- North America: North America, particularly the United States, is a prominent market for drug delivery devices. The region's strong healthcare system, significant investments in research and development, and high adoption of advanced healthcare technologies drive market growth. Increasing demand for self-administration devices, home healthcare, and targeted drug delivery solutions contribute to the high CAGR in this region.
- Europe: Europe is another region experiencing a high CAGR in the drug delivery devices market. Factors such as the presence of a well-established healthcare infrastructure, rising aging population, and increasing prevalence of chronic diseases drive the demand for advanced drug delivery devices. Countries like Germany, the United Kingdom, France, Italy, and Spain are major contributors to the growth of this market.
- Latin America: Latin America shows promising growth prospects in the drug delivery devices sector. Factors such as improving healthcare infrastructure, rising disposable income, increasing awareness about advanced healthcare technologies, and a growing focus on chronic disease management contribute to the market's expansion. Brazil, Mexico, Argentina, and Chile are among the key markets in the region.
- Middle East and Africa: The Middle East and Africa region are witnessing significant growth in the drug delivery devices market. Expanding healthcare infrastructure, increasing investment in healthcare technologies, and rising demand for improved patient care contribute to the market's high CAGR. The United Arab Emirates, Saudi Arabia, South Africa, and Egypt are key markets driving growth in this region.
The needles market is projected to reach USD 10.6 billion by 2027, at a CAGR of 6.7% during the forecast period. The major players in the Needles Market are Becton, Dickinson, and Company (US), Medtronic (Ireland), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (US), and Stryker Corporation (US).
- Published: November 2022
- Price: $ 4950
- TOC Available:
The global pharmaceutical drug delivery market in terms of revenue was estimated to be worth $1,656.9 billion in 2021 and is poised to reach $2,206.5 billion by 2026, growing at a CAGR of 5.9% from 2021 to 2026. Major players in this market includes Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).
- Published: November 2021
- Price: $ 4950
- TOC Available:
The global pen needles market in terms of revenue was estimated to be worth $1.3 billion in 2021 and is poised to reach $2.2 billion by 2026, growing at a CAGR of 11.2% from 2021 to 2026. Growth in the market is largely driven by the growing prevalence of chronic diseases and the favorable reimbursement scenario in selected countries. On the other hand, the preference for alternative modes of drug delivery, poor reimbursement in developing countries, and needle anxiety are expected to restrain the overall market growth.
- Published: June 2021
- Price: $ 4950
- TOC Available:
The global prefilled syringes market in terms of revenue was estimated to be worth $5.6 billion in 2020 and is poised to reach $8.6 billion by 2025, growing at a CAGR of 9.0% from 2020 to 2025. Becton, Dickinson and Company (US), Gerresheimer (Germany), SCHOTT AG (Germany), and West Pharmaceutical Services, Inc. (US) are the key players in the global market.
- Published: September 2020
- Price: $ 4950
- TOC Available:
The global syringes market size is projected to grow at a CAGR of 8.7%. High prevalence of chronic diseases across the globe, rising geriatric population, increasing adoption of safety syringes, technological advancements, and increasing demand for vaccines are supporting the market growth of syringes. However, high cost of safety syringes and increasing incidence of needle stick injuries are the major challenges in global Market.
- Published: November 2016
- Price: $ 4950
- TOC Available:
The North American drug delivery technologies market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5% during the forecast period. Growth in this market is primarily driven by the rising prevalence of chronic diseases, growth in the biologics market, funding initiatives for drug delivery research, and technological advancements. However, risk of needlestick injuries and side effects related to drugs are expected to restrain the growth of this market in the coming years.
- Published: August 2016
- Price: $ 4950
- TOC Available:
The European injectable drug delivery market is expected to reach $207.3 Billion by 2020 from $114.7 Billion in 2015, growing at a CAGR of 12.6% from 2015 to 2020. Factors such as rising prevalence of chronic diseases, growth of the biologics market, demand of self-injection devices, and technological advancements are driving the growth of this market. On the other hand, alternative delivery methods such as oral and transdermal, safety concerns, and blood-borne infections are hindering the growth of this market.
- Published: July 2015
- Price: $ 4950
- TOC Available:
The Europeandrug delivery market was worth $39.9 billion in the year 2012. The drug delivery technology market is segmented on the basis of route of administration into nine categories - oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery.
- Published: June 2013
- Price: $ 4950
- TOC Available:
The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.
- Published: April 2013
- Price: $ 4950
- TOC Available:
This report analyzes the basic structure of the drug-device combination market and its various submarkets. Individual markets for major products such as anti-microbial catheters, wound-care products, bone-graft substitutes, bone cement, drug-eluting stents, photodynamic therapy, artificial pancreas, and steroid eluting electrodes are further broken down into their respective sub-segments based on products, technology and applications.
- Published: November 2009
- Price: $ 4950
- TOC Available: